This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scholz, T. Articles by Lehnert, H. Search for Related Content PubMed PubMed Citation Articles by Scholz, T. Articles by Lehnert, H. Related Collections Adrenal and Hypertension Cardiovascular Endocrinology Endocrine Oncology

Current Treatment of Malignant Pheochromocytoma

Department of Endocrinology and Metabolism (T.S., H.L.), Otto von Guericke University Medical School, D-39120 Magdeburg, Germany; Warwick Medical School (H.L.), University Hospital of Coventry, Coventry CV4 7AL, United Kingdom; National Institutes of Health (G.E., K.P.), Bethesda, Maryland 20892; and Department of General, Visceral, and Vascular Surgery (H.D.), Martin Luther University, D-06099 Halle/Saale, Germany

Address all correspondence and requests for reprints to: Prof. Hendrik Lehnert, M.D., Chair of Medicine, Clinical Sciences Research Institute, Medical School Building, Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, United Kingdom. E-mail: H.Lehnert{at}warwick.ac.uk.

Context: Pheochromocytomas are rare tumors of predominantly adrenal origin that often produce and secrete catecholamines. Malignancy occurs in a variable percentage of cases depending on genetic background and tumor location. Definitive diagnosis relies on the detection of distant metastases. Treatments for malignant pheochromocytoma include surgical debulking, pharmacological control of hormone-mediated symptoms, targeted methods such as external irradiation, and systemic antineoplastic therapy. Different agents and protocols for this purpose are reviewed, and their therapeutic potential is discussed.

Evidence Acquisition: Literature on antineoplastic therapies for malignant pheochromocytoma was identified by searching the PubMed database with restriction to articles published in English during the past 30 yr.

Evidence Synthesis: Because of the rarity of the condition, no randomized clinical trials concerning the treatment of malignant pheochromocytoma have been performed. The strategy established best is [¹³¹I]meta-iodobenzylguanidine (MIBG) therapy, which is well tolerated. Similar to cytotoxic chemotherapy with cyclophosphamide, vincristine, and dacarbazine, MIBG can induce remission for a limited period in a significant proportion of patients. Octreotide as a single agent seems to be largely ineffective.

Conclusions: MIBG radiotherapy and cyclophosphamide, vincristine, and dacarbazine chemotherapy are comparable with respect to response rate and toxicity. It is unclear whether combining both can improve the outcome. Future developments may include new multimodal concepts with focus on inhibition of angiogenetic factors and heat shock protein 90. Any present or new therapeutic approach must take into account the highly variable natural course of the disease.

This article has been cited by other articles:

				K. Nomura, H. Kimura, S. Shimizu, H. Kodama, T. Okamoto, T. Obara, and K. Takano Survival of Patients with Metastatic Malignant Pheochromocytoma and Efficacy of Combined Cyclophosphamide, Vincristine, and Dacarbazine Chemotherapy J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2850 - 2856. [Abstract] [Full Text] [PDF]

				E. W. Lai, B. H. Joshi, L. Martiniova, R. Dogra, T. Fujisawa, P. Leland, R. R. de Krijger, I. A. Lubensky, A. G. Elkahloun, J. C. Morris, et al. Overexpression of Interleukin-13 Receptor-{alpha}2 in Neuroendocrine Malignant Pheochromocytoma: A Novel Target for Receptor Directed Anti-Cancer Therapy J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2952 - 2957. [Abstract] [Full Text] [PDF]

				K.-S. Park, J.-L. Lee, H. Ahn, J.-M. Koh, I. Park, J.-S. Choi, Y. R. Kim, T. S. Park, J.-H. Ahn, D. H. Lee, et al. Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 327 - 331. [Abstract] [Full Text] [PDF]

				H. K Ghayee, B. Havekes, E. P M Corssmit, G. Eisenhofer, S. R Hammes, Z. Ahmad, A. Tessnow, I. Lazurova, K. T Adams, A. T Fojo, et al. Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior Endocr. Relat. Cancer, March 1, 2009; 16(1): 291 - 299. [Abstract] [Full Text] [PDF]

				C. Jimenez, M. E. Cabanillas, L. Santarpia, E. Jonasch, K. L. Kyle, E. A. Lano, S. F. Matin, R. F. Nunez, N. D. Perrier, A. Phan, et al. Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 386 - 391. [Abstract] [Full Text] [PDF]

				R Armstrong, M Sridhar, K L Greenhalgh, L Howell, C Jones, C Landes, J L McPartland, C Moores, P D Losty, and M Didi Phaeochromocytoma in children Arch. Dis. Child., October 1, 2008; 93(10): 899 - 904. [Abstract] [Full Text] [PDF]

				J. T. Adler, G. Y. Meyer-Rochow, H. Chen, D. E. Benn, B. G. Robinson, R. S. Sippel, and S. B. Sidhu Pheochromocytoma: Current Approaches and Future Directions Oncologist, July 1, 2008; 13(7): 779 - 793. [Abstract] [Full Text] [PDF]

				D. Pasquali, V. Rossi, G. Conzo, G. Pannone, P. Bufo, A. De Bellis, A. Renzullo, G. Bellastella, A. Colao, G. Vallone, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells J. Mol. Endocrinol., June 1, 2008; 40(6): 263 - 271. [Abstract] [Full Text] [PDF]

				A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF]

				A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585. [Abstract] [Full Text] [PDF]